Streetbeat News

LXRX

Lexicon Pharmaceuticals, Inc.

https://www.lexpharma.com

Industry

Biotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Open

1.08

Mkt cap

353M

Volume

5.4M

High

1.08

P/E Ratio

-1.27

52-wk high

3.73

Low

0.97

Div yield

N/A

52-wk low

0.97

Lexicon Pharmaceuticals (LXRX) held its Q3 2024 earnings call, discussing financial results and company updates. Key participants included CEO Mike Exton and other senior executives. Analysts from Jeffries, Needham, H.C. Wainwright, Citigroup, and Leerink Partners participated in the call.

Portfolio Pulse from

November 13, 2024 | 2:00 am

Lexicon Pharmaceuticals (LXRX) reported a Q3 loss of $0.18 per share, missing the Zacks Consensus Estimate of a $0.17 loss. This is an improvement from the $0.21 loss per share a year ago.

Portfolio Pulse from

November 12, 2024 | 11:45 pm

Lexicon Pharmaceuticals reported its Q3 2024 financial results and announced an exclusive licensing agreement with Viatris for Sotagliflozin in markets outside the U.S. and Europe.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

A study published in the Journal of American Society of Nephrology highlights the efficacy and safety of sotagliflozin for people with Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD). The study found that sotagliflozin, when used with insulin, had similar effects on lowering glycated hemoglobin (HbA1c) in T1D patients with CKD as in those without CKD.

Portfolio Pulse from

November 05, 2024 | 9:30 pm

U.S. stocks rose with the Nasdaq Composite gaining over 100 points. Apple shares fell 2% despite beating Q4 earnings estimates. ChromaDex, Proto Labs, and Interface saw significant stock price increases after positive financial results. ESSA Pharma, Myriad Genetics, and Lexicon Pharmaceuticals experienced sharp declines due to negative news.

Portfolio Pulse from Avi Kapoor

November 01, 2024 | 6:35 pm

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Athira Pharma, ChromaDex, and Theriva Biologics, while Lexicon Pharmaceuticals and Myriad Genetics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 4:36 pm

U.S. stocks rose with the Nasdaq surging over 200 points, driven by strong earnings from Amazon, which reported better-than-expected Q3 results. Amazon's shares jumped 7% following the announcement. Other notable stock movements included ChromaDex, Proto Labs, and Interface, which saw significant gains due to positive earnings reports. Conversely, ESSA Pharma, Myriad Genetics, and Lexicon Pharmaceuticals experienced sharp declines due to negative news.

Portfolio Pulse from Avi Kapoor

November 01, 2024 | 4:26 pm

U.S. stocks rose with the Dow Jones gaining over 400 points. The U.S. economy added 12,000 jobs in October, below expectations. ChromaDex, Proto Labs, and Interface saw significant stock price increases due to strong earnings reports, while ESSA Pharma, Elevai Labs, and Lexicon Pharmaceuticals experienced declines.

Portfolio Pulse from Avi Kapoor

November 01, 2024 | 2:43 pm

Charter Communications shares surged 11.1% in pre-market trading after reporting better-than-expected Q3 EPS and revenues. Other notable pre-market movers include Globalstar, Theriva Biologics, and Atlassian Corporation, which saw significant gains, while ESSA Pharma and Lexicon Pharmaceuticals experienced sharp declines.

Portfolio Pulse from Avi Kapoor

November 01, 2024 | 1:15 pm

The FDA's advisory committee voted against Lexicon Pharmaceuticals' Zynquista for type 1 diabetes, citing that the benefits do not outweigh the risks. Despite this, Lexicon plans to resubmit the NDA and anticipates a potential launch in early 2025. The stock price of Lexicon Pharmaceuticals dropped significantly following the news.

Portfolio Pulse from Vandana Singh

November 01, 2024 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.